These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16645228)

  • 1. Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.
    Tehranchi R
    Med Oncol; 2006; 23(1):37-49. PubMed ID: 16645228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors.
    Tehranchi R; Fadeel B; Forsblom AM; Christensson B; Samuelsson J; Zhivotovsky B; Hellstrom-Lindberg E
    Blood; 2003 Feb; 101(3):1080-6. PubMed ID: 12393561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin.
    Hellström-Lindberg E; Kanter-Lewensohn L; Ost A
    Leuk Res; 1997 May; 21(5):415-25. PubMed ID: 9225069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts.
    Schmidt-Mende J; Tehranchi R; Forsblom AM; Joseph B; Christensson B; Fadeel B; Zhivotovsky B; Hellström-Lindberg E
    Leukemia; 2001 May; 15(5):742-51. PubMed ID: 11368434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting use of growth factors in myelodysplastic syndromes.
    Newman K; Maness-Harris L; El-Hemaidi I; Akhtari M
    Asian Pac J Cancer Prev; 2012; 13(4):1081-91. PubMed ID: 22799286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.
    Rajapaksa R; Ginzton N; Rott LS; Greenberg PL
    Blood; 1996 Dec; 88(11):4275-87. PubMed ID: 8943864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.
    Mantovani L; Lentini G; Hentschel B; Wickramanayake PD; Loeffler M; Diehl V; Tesch H
    Br J Haematol; 2000 May; 109(2):367-75. PubMed ID: 10848827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.
    Claessens YE; Bouscary D; Dupont JM; Picard F; Melle J; Gisselbrecht S; Lacombe C; Dreyfus F; Mayeux P; Fontenay-Roupie M
    Blood; 2002 Mar; 99(5):1594-601. PubMed ID: 11861273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H; Hotta T; Ichihara M; Murate T; Kobayashi M; Saito H
    Leukemia; 1994 May; 8(5):833-8. PubMed ID: 7514249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.
    Tehranchi R; Invernizzi R; Grandien A; Zhivotovsky B; Fadeel B; Forsblom AM; Travaglino E; Samuelsson J; Hast R; Nilsson L; Cazzola M; Wibom R; Hellström-Lindberg E
    Blood; 2005 Jul; 106(1):247-53. PubMed ID: 15755901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes.
    Hansen PB; Johnsen HE; Hippe E; Hellström-Lindberg E; Ralfkiaer E
    Am J Hematol; 1993 Dec; 44(4):229-36. PubMed ID: 8237992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients.
    Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Oberg G; Osterborg A; Ost A
    Blood; 1998 Jul; 92(1):68-75. PubMed ID: 9639501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
    Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
    Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin.
    Economopoulos T; Mellou S; Papageorgiou E; Pappa V; Kokkinou V; Stathopoulou E; Pappa M; Raptis S
    Leukemia; 1999 Jul; 13(7):1009-12. PubMed ID: 10400415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.